Working to Eradicate Gynecologic Cancers

Scientific Plenary V

Sunday, March 29, 2015: 2:15 PM-3:05 PM
International Ballroom (Hilton Chicago)
Description: You will hear presentations from 4 authors describing novel biomarkers in ovarian cancer to predict disease status, prognosis, and response to therapy, followed by an expert distillation of how these projects fit into the "big picture" of the current science behind ovarian cancer biomarkers.
Moderators:  Charles N. Landen Jr., MD, University of Virginia School of Medicine, Charlottesville, VA and Barbara Stulken Norquist, MD, University of Washington, Seattle, WA
2:15 PM
Introductory Remarks
C. N. Landen Jr.1 and B. S. Norquist2
1University of Virginia School of Medicine, Charlottesville, VA, 2University of Washington, Seattle, WA
 
2:20 PM
24
Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
K. S. Tewari1, M. Sill2, B. J. Monk3, R. T. Penson4, H. Lankes2, M. M. Leitao5, L. M. Ramondetta6, L. Van Le7, D. L. Richardson8, L. M. Landrum9, P. A. DiSilvestro10, K. Behbakht11, F. R. Ueland12, H. Michael13 and M. J. Birrer14
1UC Irvine Medical Center, Orange, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4Massachusetts General Hospital/Harvard University, Boston, MA, 5Memorial Sloan Kettering Cancer Center, New York, NY, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7University of North Carolina at Chapel Hill, Chapel Hill, NC, 8University of Texas Southwestern Medical Center, Dallas, TX, 9The University of Oklahoma, Oklahoma City, OK, 10Women and Infants Hospital, Brown University, Providence, RI, 11University of Colorado Denver, Aurora, CO, 12University of Kentucky Medical Center, Lexington, KY, 13Indiana University School of Medicine, Indianapolis, IN, 14Massachusetts General Hospital Cancer Center/Harvard University, Boston, MA
 
2:29 PM
25
TP53 mutations in circulating tumor DNA for response monitoring in patients with high grade serous carcinoma of ovary
Y. M. Kim1, S. W. Lee1, H. Y. Lee2, S. E. Lee2, Y. R. Park3, J. H. Kim1, Y. T. Kim1 and J. H. Nam1
1University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea, 2Asan Institute for Life Sciences, Seoul, South Korea, 3Asan Medical Center, Seoul, South Korea
 
2:38 PM
26
Tumor-derived serum exosomal microRNA as a novel biomarker for high-grade serous carcinoma
V. Broach, J. J. Mueller, B. Schlappe, F. Bogomolniy, M. Bisogna, F. Dao, P. Jelinic and D. A. Levine
Memorial Sloan Kettering Cancer Center, New York, NY
 
2:47 PM
27
Serum mitochondrial DNA shows a greater effect size than CA-125 in predicting survival in epithelial ovarian cancer
K. S. Grzankowski, N. Khan, N. V. Kolomeyevskaya, K. M. Moysich, K. Eng, S. B. Lele, K. O. Odunsi and B. H. Segal
Roswell Park Cancer Institute, Buffalo, NY
 
2:56 PM
Distillation - Biomarkers
E. C. Kohn
National Cancer Institute, Bethesda, MD
 
3:06 PM
Moderator Scientific Plenary V
C. N. Landen Jr.
University of Virginia School of Medicine, Charlottesville, VA
 
3:06 PM
Moderator, Scientific Plenary V
B. S. Norquist
University of Washington, Seattle, WA
 
See more of: Scientific Plenary
<< Previous Course | Next Course >>